Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANAIRAMA study of frevecitinib in severe asthma
2023-509125-41-00Phase 2Authorised
- Sponsor
- Kinaset Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of frevecitinib in severe asthma (4 arms), sponsored by Kinaset Therapeutics. Primary endpoint: Change in predose (pre-bronchodilator) FEV1 from baseline to Week 12. Planned start Oct 2026; status: authorised.
02
Drugs
frevecitinib
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2023-509125-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509125-41-00.